...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients
【24h】

Effectiveness of moxonidine to reduce atrial fibrillation burden in hypertensive patients

机译：莫索尼定减轻高血压患者房颤负担的功效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is substantial evidence that the autonomic system plays an important part in the pathogenesis of atrial fibrillation (AF). It appears that, although some patients have a preponderantly sympathetic or vagal overactivation leading to AF, a combined sympathovagal drive is most commonly responsible for AF triggering. The purpose of this hypothesis-generating study was to test whether moxonidine, a centrally acting sympathoinhibitory agent, on top of optimal antihypertensive treatment, can lead to a decrease in AF burden in hypertensive patients with paroxysmal AF. This was a prospective, double-blind, 1-group, crossover study. Hypertensive patients with paroxysmal AF sequentially received treatment with placebo and moxonidine for two 6-week periods, respectively. The change in AF burden (measured as minutes of AF per day in three 48-hour Holter recordings) between the 2 treatment periods was the primary outcome measure. Fifty-six patients (median age 63.5 years, 35 men) were included. During moxonidine treatment, AF burden was reduced from 28.0 min/day (interquartile range [IQR] 15.0 to 57.8) to 16.5 min/day (IQR 4.0 to 36.3; p <0.01). European Heart Rhythm Association symptom severity class decreased from a median of 2.0 (IQR 1.0 to 2.0) to 1.0 (IQR 1.0 to 2.0; p = 0.01). Systolic blood pressure levels were similar in the 2 treatment periods, whereas diastolic blood pressure was lower (p <0.01) during moxonidine treatment. The most frequent complaint was dry mouth (28.6%). No serious adverse events were recorded. In conclusion, treatment with moxonidine, a centrally acting sympathoinhibitory agent, results in reduction of AF burden and alleviation of AF-related symptoms in hypertensive patients with paroxysmal AF.
机译：有大量证据表明，自主系统在心房颤动（AF）的发病机理中起着重要作用。看来，尽管一些患者的交感神经或迷走神经过度活化导致房颤，但合并交感迷走神经驱动最常引起房颤触发。进行这项假设的研究的目的是测试在最佳抗高血压治疗的基础上，莫索尼定（一种中央作用的交感神经抑制剂）是否可以减少患有阵发性AF的高血压患者的AF负担。这是一项前瞻性，双盲，1组，交叉研究。患有阵发性房颤的高血压患者依次接受安慰剂和莫索尼定的治疗，为期两个6周。主要结局指标是两个治疗期之间房颤负担的变化（以三个48小时动态心电图记录中每天的房颤分钟数衡量）。包括56例患者（中位年龄63.5岁，男35例）。在莫索尼定治疗期间，AF负担从28.0分钟/天（四分位间距[IQR] 15.0至57.8）降低到16.5分钟/天（IQR 4.0至36.3; p <0.01）。欧洲心律协会症状严重程度等级从中位数2.0（IQR 1.0至2.0）降至1.0（IQR 1.0至2.0; p = 0.01）。在两个治疗期间，收缩压水平相似，而在莫索尼定治疗期间舒张压较低（p <0.01）。最常见的投诉是口干（28.6％）。没有记录到严重的不良事件。总之，用莫索尼定（一种中枢性交感抑制剂）治疗可减轻患有阵发性AF的高血压患者的AF负担并减轻其与AF相关的症状。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号